Scott D. Lee

University of Washington — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

32h-index5.5kcitations211works4.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(128), Microscopic Colitis(76), Eosinophilic Esophagitis(39), Immunodeficiency and Autoimmune Disorders(24), Autoimmune and Inflammatory Disorders(17)

Publications208 total

Early Lesions Seen in Colonoscopic Surveillance Biopsies from Regions where Colorectal Carcinoma Developed in Patients with Inflammatory Bowel Diseases are Often Not Overtly Dysplastic
2025Open Access
Comparison of outcomes with different approaches to antithrombotic therapy after venous stenting
Blood·2025Open Access
S2045 Endoscopic Remission Rates With Risankizumab Following Treatment Failure With Ustekinumab
The American Journal of Gastroenterology·2025
Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn’s Disease
Inflammatory Bowel Diseases·2025Open Access
Upadacitinib Maintenance Therapy in Crohn’s Disease: Final Results From the Randomized Phase 3 U-ENDURE Study
Clinical Gastroenterology and Hepatology·2025Open Access
Somatic and Stem Cell Bank to study the contribution of African ancestry to dementia: African iPSC Initiative
Alzheimer s & Dementia·2025· 1 citedOpen Access
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study
The American Journal of Gastroenterology·2025· 2 citedOpen Access
Upadacitinib Results in Endoscopic Remission in Patients With Inflammatory Bowel Disease and Prior Tofacitinib Failure
Journal of Clinical Gastroenterology·2025· 2 cited
Somatic and Stem Cell Bank to Study the Contribution of African Ancestry to Dementia: African iPSC Initiative
2025Open Access
Certolizumab Pegol Treatment in Patients With Crohn’s Disease: Final Safety Data From the SECURE Registry
Crohn s & Colitis 360·2024· 1 citedOpen Access
S43 Mirikizumab Improved the Quality of Life in Patients with Crohn’s Disease Regardless of Their Previous Biologic Failure Status: Results from the Phase 3 VIVID-1 Study
The American Journal of Gastroenterology·2024
IMPLEMENTATION OF ACOUSTIC CONTRAST CONTROL BETWEEN THE SEATS IN A CAR CABIN-LIKE ROOM USING LOUDSPEAKERS ON FLOOR
2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Inflammatory Bowel Diseases·2024· 20 citedOpen Access
S1476 Safety of Long-Term Ozanimod Treatment Up to 5 Years in Patients With Moderately to Severely Active Ulcerative Colitis: An Interim Analysis of the True North Open-Label Extension
The American Journal of Gastroenterology·2024· 1 cited
Mycophenolate Mofetil Appears Effective for the Treatment of Patients With Refractory Crohn’s Disease
Crohn s & Colitis 360·2024Open Access
S1436 Mirikizumab Improves Quality of Life in Patients With Moderately to Severely Active Crohn’s Disease: Results from the Phase 3 VIVID-1 Study
The American Journal of Gastroenterology·2024
S1450 Long-Term Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment: Results From the LUCENT-3 Open-Label Extension Study
The American Journal of Gastroenterology·2024· 1 cited
P78 Upadacitinib maintenance therapy in moderate-to-severe crohn’s disease: final results from the phase 3 U-ENDURE study
Poster presentations·2024
Sa1782 SIGNIFICANT DISCORDANCE BETWEEN ENDOSCOPY AND BIOPSY HISTOLOGY IN ASSESSING INFLAMMATION IN ACTIVE CROHN'S DISEASE
Gastroenterology·2024
Real-World Patterns and Economic Burden Associated With Treatment Failure With Advanced Therapies in Patients With Moderate-to-Severe Ulcerative Colitis
Crohn s & Colitis 360·2024· 4 citedOpen Access
page 1 of 11Next →

Frequent Co-authors

William J. Sandborn(8), Séverine Vermeire(5), Edward V. Loftus(5), Corey A. Siegel(5), Michael D. Saunders(5), Geert D’Haens(5), Brian G. Feagan(4), Bruce E. Sands(4), Marla C. Dubinsky(4), Julián Panés(4), Laurent Peyrin‐Biroulet(4), Cynthia W. Ko(4), Jerrold S. Petrofsky(4), Stefan Schreiber(4), Remo Panaccione(4), Kindra Clark‐Snustad(4), Subrata Ghosh(3), Kris V. Kowdley(3), Michael B. Kimmey(3), Édouard Louis(3)